December 22, 2020 Non Regulatory LIDDS has decided to apply for listing of the company’s shares on Nasdaq Stockholm Main Market in 2021
December 18, 2020 Non Regulatory Update on Chinese Conditional Market Approval (CMA) for Liproca® Depot
November 18, 2020 Non Regulatory A review article defines LIDDS as a key player in TLR9 agonist research field and being the only provider having a sustained release product in development
October 26, 2020 Regulatory LIDDS’ NanoZolid-TLR9 agonist demonstrates strong and durable preclinical anti-tumoral effect
October 19, 2020 Non Regulatory LIDDS announces outcome of subscription of shares in the incentive programs 2017/2020
August 20, 2020 Regulatory LIDDS licensee, Puheng Pharma, evaluates a novel expeditated regulatory path for Liproca Depot in China
June 11, 2020 Regulatory LIDDS announces a capital raise of a total of approximately SEK 59.3 million and accordingly secures long-term financing
May 19, 2020 Regulatory Correction of press release: Liproca Phase IIb study results indicate cancer control
May 18, 2020 Regulatory LIDDS announces positive meeting with the Swedish Medical Products Agency, confirming the Liproca® Depot Phase III study design
March 25, 2020 Regulatory LIDDS announces positive preclinical data for NanoZolid®-TLR9 agonist project
February 11, 2020 Regulatory LIDDS: Last patient treated in Liproca® Depot open label extension study
January 14, 2020 Non Regulatory LIDDS: The United States Patent and Trademark Office has registered the LIDDS trademark NANOZOLID in the US
January 13, 2020 Non Regulatory LIDDS: Stockpicker´s buy recommendation for 2020 picks LIDDS share as one of twelve attractive Swedish companies
January 9, 2020 Regulatory LIDDS obtains novel US product patent that significantly broadens protection on NanoZolid® pharmaceuticals